CD274 and triple-negative breast carcinoma: While immunotherapy targeting PD-L1 in combination with chemotherapy has shown efficacy in metastatic triple negative breast cancer [16], HR+ breast cancer is poorly responsive to PD-1/PD-L1 blockade [17].